BiographyRecognized by Chambers & Partners as one of the top cannabis lawyers in the United States, Charlie Alovisetti is a partner at Vicente Sederberg and chair of the firm's Corporate Department. He focuses his practice on advising investors, companies, and other law firms on the nuances of executing corporate transactions involving licensed and ancillary cannabis companies. Prior to joining VS, Charlie worked as an associate in the New York offices of Latham & Watkins and Goodwin, where he represented public companies and private equity sponsors and their portfolio companies in a range of corporate transactions.
Charlie has worked on licensed transactions in Canada and all the major cannabis markets in the United States. He understands the state and local issues that commonly arise in stock and asset acquisitions as well as issues involved in management companies and other alternative structures.
He has provided guidance on structuring and corporate matters to applicants in merit licensing processes in Connecticut, Hawaii, Illinois, Maryland, Missouri, New Jersey, Ohio, Pennsylvania, Utah, Virginia, and several local jurisdictions. Charlie also has experience counseling portfolio and emerging growth companies with respect to general corporate and commercial matters and all aspects of compensation arrangements. In addition to his corporate practice, he provides specialized cannabis counsel to non-cannabis companies seeking to evaluate the risks of entering the cannabis space and structure their investments to reduce risks.
Charlie holds a Bachelor of Arts, with honors, from McGill University and a law degree from Columbia Law School, where he was a Harlan Fiske Stone Scholar. He is admitted to practice in Colorado and New York, and is a Level One Interpener. Recognized as a thought leader and experienced practitioner in the areas of cannabis M&A and financings, Charlie is an author, a frequent speaker at events, and has participated in a number of working groups in Colorado related to the cannabis industry, including the most recent group focused on HB19-1090—the bill that permitted public company investment.